Form 4: Arcutis EVP Sells Shares for Tax Obligations

Arcutis Biotherapeutics' EVP Chief Commercial Officer, Larry Todd Edwards, sold 4,504 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Larry Todd Edwards, the Executive Vice President and Chief Commercial Officer of Arcutis Biotherapeutics, Inc. (ARQT), reported transactions involving the company's common stock.
• On October 2, 2025, Mr. Edwards sold a total of 4,504 shares of common stock in two separate transactions.
• The sales were executed to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) that were granted on February 22, 2024.
• These transactions were conducted under a Rule 10b5-1 pre-arranged trading plan.
• Following these reported transactions, Mr. Edwards directly beneficially owns 179,324 shares of Arcutis Biotherapeutics common stock.
• The reported beneficial ownership includes 724 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there is a reduction in insider ownership, it is a non-discretionary sale for tax purposes related to RSU vesting, which is a normal part of executive compensation. The executive also made an additional purchase through an Employee Stock Purchase Plan, indicating continued investment.

Positives

• The vesting of Restricted Stock Units indicates the realization of equity compensation for the executive.
• The purchase of 724 shares under the Employee Stock Purchase Plan on May 31, 2025, demonstrates continued investment by the executive in the company.

Negatives

• The direct beneficial ownership of common stock by the EVP Chief Commercial Officer was reduced by 4,504 shares due to the tax-related sales.

Future Outlook

NA

Management Comments

• The sales reported represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units granted on February 22, 2024.
• The Reporting Person undertakes to provide full information regarding the number of shares sold at each respective price within the stated ranges upon request.

Industry Context

NA

Stakeholder Impact

• Shareholders will observe a slight reduction in the direct beneficial ownership of common stock by a key executive, though this is for tax purposes related to compensation and not a discretionary sale.
• The transaction provides transparency regarding executive compensation and shareholdings.

Key Dates

Keywords

Arcutis Biotherapeutics, ARQT, Insider Trading, Form 4, Executive Compensation, Restricted Stock Units, RSU Vesting, Tax Withholding, Rule 10b5-1 Plan, Employee Stock Purchase Plan